<DOC>
	<DOCNO>NCT01269515</DOCNO>
	<brief_summary>Chronic immune activation central feature HIV-infection , degree activate T-cells well predictor disease progression mortality plasma viral load . The study hypothesis anti-inflammatory substance etoricoxib dampen chronic immune activation improve effect T-cell dependent vaccine HIV-1 infect patient . The aim present study explore efficacy study drug marker immune activation vaccine response , well safety study drug , HIV-infected patient receive antiretroviral therapy .</brief_summary>
	<brief_title>Immunomodulating Therapy Improved Vaccination Responses Cox-2 Inhibitor HIV-infected Patients</brief_title>
	<detailed_description>The current trial base observation augment level cyclic adenosine monophosphate ( cAMP ) contribute T cell dysfunction HIV-infected patient . In T cell , cAMP trigger protein kinase A ( PKA ) - Csk - Lck inhibitory pathway inhibits proximal T cell receptor ( TCR ) signal event . This mechanism may also involve inhibitory function regulatory T cell . The investigator hypothesize elevated level cAMP T cell HIV-infected individual result increase production prostaglandin E2 ( PGE2 ) follow activation-induced expression cyclooxygenase type 2 ( COX-2 ) lymphoid tissue . Although investigator identify even COX-2 positive T cell HIV-infected individual , activate monocyte may major source PGE2 ; high level COX-2 produce de novo number stimulus , particularly lipopolysaccharide ( LPS ) . Circulating LPS indeed increase untreated chronic HIV infection due enhance translocation microbial material correlate chronic immune activation disease progression . In three precede clinical explorative trial , investigator demonstrate COX-2 inhibition COX-2 inhibitor ( COX-2i ) improve immune function HIV patient , first two study include patient antiretroviral treatment ( ART ) . In third trial investigator also show first time treatment COX-2i able downregulate chronic immune activation improve T cell function ( efficacy T cell-dependent vaccine ) asymptomatic HIV-infected patient use ART . In patient , chronic immune activation dampen demonstrate ; CD38 density CD8+ T cell ( primary endpoint ) decrease 24 % study week 12 . This reduction could extrapolate possible improvement CD4+ T cell loss 30 CD4 cell per ul per year approximate mean CD4 loss 60 per ul per year . These data found basis support study GLOBVAC call program Norwegian Research Council ( grant application current study ) .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
	<criteria>confirm diagnosis HIV infection &lt; 8 year prestudy HIVrelated clinical manifestation include acute HIV infection current indication use antiretroviral treatment CD4+ count &gt; 350 x 106 /l HIV RNA &gt; 2000 copies/ml On current antiretroviral treatment concomitant sporadic use NSAID , corticosteroid immune modulate therapy include interferonalpha cholesterol &gt; 7 M treatment hypertension antihypertensive treatment indicated inclusion cardiovascular event stroke parent , sibling offspring occur &lt; 55 year age elevate serum creatinine diabetes type I II know hypersensitivity etoricoxib , capsule substance sulphonamides active peptic ulcer gastrointestinal haemorrhage history asthma , acute rhinitis , nasal polyp , angioneurotic oedema , urticaria allergic reaction take acetyl salicylic acid NSAID include COX2 inhibitor pregnancy insufficient birth control females breastfeed seriously derange liver function creatine clearance &lt; 30 ml/min inflammatory bowel disease heart failure ( NYHA IIIV ) establish ischaemic heart disease , peripheral arteriosclerosis and/or cerebrovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Cox-2 inhibitor</keyword>
	<keyword>HIV</keyword>
	<keyword>immune activation</keyword>
	<keyword>immune modulating</keyword>
	<keyword>progression marker</keyword>
	<keyword>vaccine</keyword>
</DOC>